In vitro activities of LY163892, cefaclor, and cefuroxime
- PMID: 3348605
- PMCID: PMC172113
- DOI: 10.1128/AAC.32.1.131
In vitro activities of LY163892, cefaclor, and cefuroxime
Abstract
The in vitro activity of LY163892, a synthetic oral cephalosporin, was compared with those of cefaclor and cefuroxime against 1,193 clinical isolates. MIC ranges and MICs for 50 and 90% of isolates of the three cephalosporins were comparable. The activities of LY163892 and cefaclor were, however, highly inoculum dependent against beta-lactamase-positive Haemophilus influenzae and Staphylococcus aureus; that of cefuroxime was not. LY163892 and cefuroxime appeared stable in microdilution trays stored at 5 and -20 degrees C for 5 weeks, in contrast to cefaclor which remained stable for more than a week only at -5 degrees C.
Similar articles
-
In vitro activity and beta-lactamase stability of LY163892.Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):549-51. doi: 10.1007/BF01962613. Eur J Clin Microbiol Infect Dis. 1988. PMID: 3141170
-
[Comparative antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria].Pathol Biol (Paris). 1990 May;38(5):343-6. Pathol Biol (Paris). 1990. PMID: 2367150 French.
-
Comparative in-vitro activity of a new oral carbacephem, LY163892.J Antimicrob Chemother. 1988 Oct;22(4):445-56. doi: 10.1093/jac/22.4.445. J Antimicrob Chemother. 1988. PMID: 3060458
-
The cephalosporins: activity and clinical use.Drugs. 1980 Aug;20(2):137-54. doi: 10.2165/00003495-198020020-00007. Drugs. 1980. PMID: 6995096 Review.
-
Cephalosporins.2021 Dec 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Dec 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643977 Free Books & Documents. Review.
Cited by
-
Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins.Antimicrob Agents Chemother. 1988 Oct;32(10):1477-80. doi: 10.1128/AAC.32.10.1477. Antimicrob Agents Chemother. 1988. PMID: 3190179 Free PMC article.
-
Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.Drugs. 1996 Jul;52(1):125-58. doi: 10.2165/00003495-199652010-00009. Drugs. 1996. PMID: 8799689 Review.
-
Pharmacokinetics of loracarbef and interaction with acetylcysteine.Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):851-5. doi: 10.1007/BF01960891. Eur J Clin Microbiol Infect Dis. 1992. PMID: 1468429 Clinical Trial.
-
Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.Infection. 1992 May-Jun;20(3):176-82. doi: 10.1007/BF01704619. Infection. 1992. PMID: 1463527 Clinical Trial.
-
In vitro activity and beta-lactamase stability of LY163892.Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):549-51. doi: 10.1007/BF01962613. Eur J Clin Microbiol Infect Dis. 1988. PMID: 3141170
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical